MERCK Sharp & Dohme has welcomed the addition of its Steglatro (ertugliflozin) to the Pharmaceutical Benefits Scheme, with the SGLT2-inhibitor listed for adults with uncontrolled type 2 diabetes mellitus as evidenced by HbA1c blood glucose levels.
The Authority Required indication is for Steglatro use in combination with metformin or a sulfonylurea.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Dec 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Dec 18
